03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Synacthen Retard* : | |
Type | Medicine Non Marketed |
Originator | B |
Agent | Mephico |
Distributor | Mephico |
Laboratory | Mephico Laboratories |
Responsible Party | Mephico SAL |
Origin | Lebanon |
Manufacturer | Mephico SAL* |
Origin | Lebanon |
ATC | H01AA02 |
Synacthen Retard* :
Synacthen Retard* :
Synacthen Retard* :
Synacthen Retard* :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal distension | Not known |
Abscess | Not known |
Acute kidney injury | Very rare |
Adrenal haemorrhage | Very rare |
Alkalosis hypochloraemic | Not known |
Amoebiasis | Not known |
Anaphylactic shock | Not known |
Angioedema (Angioneurotic oedema) (Quincke oedema) | Not known |
Aseptic necrosis | Not known |
Blood potassium decreased | Not known |
Calcium low | Not known |
Cardiac failure | Not known |
Cephalea | Not known |
Convulsion | Not known |
Cushing's syndrome | Not known |
Diabetes mellitus precipitated | Not known |
Dyspnoea (dyspnea) | Not known |
Ecchymosis | Not known |
Emotional lability | Not known |
Eruption acneiform | Not known |
Erythema facial | Not known |
Exophthalmos (Bulging eyes) | Not known |
Fluid retention | Not known |
Fracture | Not known |
Gastric haemorrhage | Not known |
Gastric perforation | Not known |
Gastric ulcer | Not known |
Glaucoma | Not known |
Glucose tolerance decreased | Not known |
Growth failure | Not known |
Hirsutism | Not known |
Hot flush | Not known |
Hyperglycaemia | Not known |
Hypersensitivity reactions | Not known |
Hypertension | Not known |
Impaired healing | Not known |
Increased appetite | Not known |
Infection susceptibility increased | Not known |
Injection site reaction | Not known |
Intracranial hypertension (Intracranial pressure increased) | Not known |
Intraocular pressure increased | Not known |
Leukocytosis | Not known |
Macular degeneration | Not known |
Malaise | Not known |
Menstruation irregular | Not known |
Muscle atrophy | Not known |
Muscle weakness | Not known |
Nausea | Not known |
Necrotizing angiitis | Not known |
Nitrogen balance negative | Not known |
Oesophagitis ulcerative | Not known |
Osteoporosis | Not known |
Pancreatitis | Not known |
Papilloedema | Not known |
Pathological fracture | Not known |
Petechiae | Not known |
Pigmentation disorder | Not known |
Posterior subcapsular cataract | Not known |
Pruritus | Not known |
Psychological disorder | Not known |
Skin test negative ( | Not known |
Skin thinning | Not known |
Sodium retention | Not known |
Steroid myopathy | Not known |
Sweating increased (Excessive sweating) (Hyperhydrosis) | Not known |
Tendon rupture | Not known |
Thromboembolism | Not known |
Tuberculosis | Not known |
Urticaria | Not known |
Vertigo | Not known |
Virilism | Not known |
Vomiting | Not known |
Weight increased (weight gain) | Not known |
Synacthen Retard* :
Different Units By MoH Code
Synacthen Retard* MoH 4553 :
Form | Solution for injection |
Packaging | Ampoules |
Package Size | 1x1ml |
Strength | 1mg/ml |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 24275 |
Submission date | 01/01/1979 |
Registration Year | 1979 |
Archived Date | 2008 |
Price Comparison
● Country: | New Zealand |
● Package Size: | 1 inj |
● Exfactory Price: | 690 NZD |
● Reference: | New Zealand Pharmaceutical Management Agency |
● Pricing Date: | 01/04/2020 |
● Type: | Medicine Authorised |
You have to register to view this info
Drop File